No insider purchase over the last 90 days. The latest, by 황금민, was filed 05 Jun 2026.
Gencurix Inc.: what insiders have been doing
This page follows insider dealings at Gencurix Inc. as filed with DART (FSS), a company from the Health Care sector. Between 31 October 2025 and 31 October 2026, 5 insiders published 12 filings.
Both sides are active: 4 purchases and 3 sales worth €12k, from 3 insiders and 2 insiders respectively. The amount is not disclosed for 6 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 1 senior executive and 1 chief executive. The largest single trade was a sale of €12k by 문영호, published on 5 March 2026, equal to 0.046% of the market capitalisation.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 12 filings, this issuer sits above that mark. Since 2021, the database holds 25 purchases and 6 sales by insiders of the company.
The latest purchase dates back some time: it was published 158 days ago, on 5 June 2026. Filings reach the DART (FSS) feed a median of 8 days after the trade. That lag is the time during which only the insider knows about the trade.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- +8.5%Entry ₩1,804 · Close 29 Oct 2026 ₩1,957
- +26.9%Entry ₩1,542 · Close 29 Oct 2026 ₩1,957
- -50.5%Entry ₩3,200 · Close at T+365 ₩1,583
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- ●Executives0DART
- 9,000 sharesShareKRXDART:20260605000568Canonical exit: 3 Sept 2026 (T+90)
- 0KRXDART:20260409002568
- 5,753 sharesKRXDART:20260309001624
- ●Executives0DART
- 5,753 shares@ ₩3,470.000.046% mcap100.0% of flowShareKRXDART:20260305001449
- 0KRXDART:20260225005334
- 40,000 sharesKRXDART:20260205000528
- 191,210 sharesKRXDART:20260128000295Canonical exit: 26 Apr 2026 (T+90)
- 0KRXDART:20260115000425
- 6,230,443 sharesKRXDART:20260107000618Canonical exit: 30 Mar 2026 (T+90)
- 6,060,339 sharesShareKRXDART:20260107000624Canonical exit: 7 Apr 2026 (T+90)
- 9,000 sharesShareKRXDART:20241021000188
- 780,000 sharesKRXDART:20240801000222Canonical exit: 23 Oct 2024 (T+90)
- ShareKRXDART:20240801000225Canonical exit: 24 Oct 2024 (T+90)
- 2,697 sharesKRXDART:20240405003199
- 24,753 shares@ ₩2,828.0080.3% of flowShareKRXDART:20240405003214Canonical exit: 27 Jun 2024 (T+90)
- 780,000 sharesKRXDART:20231121000080Canonical exit: 13 Feb 2024 (T+90)
- 780,000 sharesKRXDART:20230922000420Canonical exit: 20 Dec 2023 (T+90)
- ●Executives0DART
- 780,000 sharesKRXDART:20230428000544Canonical exit: 20 Jul 2023 (T+90)
- ShareKRXDART:20230428000607
- ShareKRXDART:20230428000564
25 of 53 declarations
About Gencurix Inc.
젠큐릭스 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative diagnostic solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
